<DOC>
	<DOCNO>NCT00718536</DOCNO>
	<brief_summary>The co-administration raltegravir medicinal product knouwn potent UGT1A1 inhibitor , atazanavir , may increase plasma level raltegravir . So daily raltegravir ( 800 mg QD ) , instead twice day ( 400 mg BID ) , could appropriate therapeutic option HIV-infected patient also receive atazanavir-containing antiretroviral regimen . In study , pharmacokinetic data support hypothesis recover .</brief_summary>
	<brief_title>Clinical Trial Assessing Once Daily Raltegravir Administration ( 800 mg QD ) HIV-1-Infected Patients Receiving Unboosted Atazanavir ( 400 mg QD ) - Based Antiretroviral Therapy</brief_title>
	<detailed_description>Treatment adherence crucial effectiveness antiretroviral therapy , , attempt promote treatment adherence patient , daily ( QD ) regimens preferred rather twice daily ( BID ) regimens . The dose 400 mg BID raltegravir recently license treatment human immunodeficiency virus ( HIV-1 ) infection treatment-experienced adult patient . Raltegravir eliminate mainly metabolism via uridine diphosphate glucuronyl transferase ( UGT1A1 ) -mediated glucuronidation pathway . Thus , co-administration raltegravir medicinal product know potent UGT1A1 inhibitor , atazanavir , may increase plasma level raltegravir . Based data , could hypothesize daily raltegravir ( 800 mg QD ) could appropriate therapeutic option HIV-infected patient also receive atazanavir-containing antiretroviral regimen . However , pharmacokinetic data support hypothesis lacking .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Patients age 18 65 year old document HIV1 infection . 2 . Patients antiretroviral regimen include atazanavir 400mg QD least 4 week . 3 . Complete virological suppression ( &lt; 50 copies/mL ) least 12 month . 4 . Voluntary write informed consent . 5 . Ability compliance visit schedule . 1 . AIDS define condition within 4 week prior initiation study . 2 . Concomitant treatment ritonavir well inducer ( NNRTI , rifampin , carbamazepine , phenytoin , phenobarbital , valproic acid , etc ) inhibitor ( probenecid , etc ) uridine diphosphate glucuronyl transferase within 2 week screen visit . 3 . Concomitant therapy tenofovir . 4 . History suspect poor adherence HAART . 5 . History drug allergy raltegravir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Atazanavir</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>once-daily</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>HIV</keyword>
</DOC>